[The immunomodulation of the natural killer activity of the splenocytes in C3HA mice during hepatoma 22a growth].
Filatova. N A NA; Malygin. A M AM; Goriunova. L B LB; Fel'. V Ia VIa; Khavinson. V Kh VKh
Key Findings
- Thymogen injection increased NK cell activity in mouse spleen
- Thymogen modestly reduced tumor growth rate in the hepatoma model
- Cyclophosphamide showed a stronger tumor‑suppressing effect, likely due to direct toxicity
Practical Outcomes
- Thymogen may have mild immune‑enhancing properties, but the evidence is limited to a specific mouse cancer model. No human dosing, safety, or efficacy data are available, so it isn’t ready for practical use in longevity or performance protocols.
Summary
In a mouse study, a single dose of the peptide thymogen before introducing liver cancer cells boosted the mice's natural killer (NK) immune cells and slightly slowed tumor growth, though the effect was weaker than a chemotherapy drug.
Abstract
A single injection of C3HA mice with various immunomodulators-ds-RNA, thymogene (TM) and cyclophosphamide (CY)--performed one day before transplantation of syngeneic hepatoma 22a cells led to a decrease in the tumor growth rate. The most prominent effect was found following the CY treatment. The NK cell activity estimated per spleen of mice treated with ds-RNA and TM was seen increased in comparison with the control mice not given the modulators. The rate of tumor growth was due probably to this fact. The protective effect of CY may be accounted for by a direct action of this agent on tumor cells.
Study Information
pubmed
1990